As an oral, ATP-competitive pan-AKT kinase inhibitor, capivasertib holds considerable promise for targeting the altered AKT signaling pathway, presenting new therapeutic opportunities for patients with advanced breast cancer who have progressed following prior aromatase inhibitor therapy, with or without a CDK4/6 inhibitor. This evidence concerns the gene CYP19A1 and breast cancer.